|
David Ludvigson joined Nanogen in May 2003 and has served on the Nanogen board since 1996. Over the last 20 years, he has held key operational positions, including COO, CFO and VP of Sales and Marketing, at leading biotechnology and technology companies. Most recently, Mr. Ludvigson was President and Chief Executive Officer of Black Pearl, a leader in event-based business intelligence software for enterprises. Prior to Black Pearl, he was President of InterTrust Technologies, a well-respected digital rights management software company. From 1998 to 2000, he was Chief Financial Officer and then Chief Operating Officer at Matrix Pharmaceuticals, a public company focused on developing cancer therapeutics, where he was responsible for operations, finance and administration functions. From 1993 to 1996, he was Vice President and CFO of IDEC during which time he helped conclude an alliance with Genentech for Rituxan®, a cancer therapeutic, considered one of the most successful alliances in the biotech industry. Mr. Ludvigson recently joined the board of directors for Argonaut Technologies, a maker of instruments and chemistry consumables for drug discovery. Mr. Ludvigson received both a B.S. and M.S. degree from University of Illinois, Champaign-Urbana campus. | 